Medications that modify lipids are frequently recommended to lower atherogenic lipid quantities and to protect against ASCVD.379 Given the significant influence of PCSK9 deficiency upon the significant decrease in blood LDL-C levels, along with the safety demonstrated by the absence or complete lack of PCSK9 in animal models and human studies,23,69–71,122,125 it seemed promising that PCSK9-iT could be an effective strategy for LDL-C reduction. The gene discussed is PCSK9; the disease is atherosclerosis.